Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
CONTEXT: Nonalcoholic fatty liver disease is associated with risk factors for cardiovascular disease, particularly increased plasma triglyceride (TG) concentrations and insulin resistance. Fenofibrate and extended release nicotinic acid (Niaspan) are used to treat hypertriglyceridemia and can affect fatty acid oxidation and plasma free fatty acid concentrations, which influence intrahepatic triglyceride (IHTG) content and metabolic function. OBJECTIVE: The objective of the study was to determine the effects of fenofibrate and nicotinic acid therapy on IHTG content and cardiovascular risk factors. EXPERIMENTAL DESIGN AND MAIN OUTCOME MEASURES: We conducted a randomized, controlled trial to determine the effects of fenofibrate (8 wk, 200 mg/d), Niaspan (16 wk, 2000 mg/d), or placebo (8 wk) on IHTG content, very low-density lipoprotein (VLDL) kinetics, and insulin sensitivity. SETTING AND PARTICIPANTS: Twenty-seven obese subjects with nonalcoholic fatty liver disease (body mass index 36 +/- 1 kg/m(2), IHTG 23 +/- 2%) were studied at Washington University. RESULTS: Neither fenofibrate nor Niaspan affected IHTG content, but both decreased plasma TG, VLDL-TG, and VLDL-apolipoprotein B concentrations (P < 0.05). Fenofibrate increased VLDL-TG clearance from plasma (33 to 54 ml/min; P < 0.05) but not VLDL-TG secretion. Niaspan decreased VLDL-TG secretion (27 to 15 micromol/min; P < 0.05) without affecting clearance. Both fenofibrate and Niaspan decreased VLDL-apolipoprotein B secretion (1.6 to 1.2 and 1.3 to 0.9 nmol/min, respectively; P < 0.05). Niaspan reduced hepatic, adipose tissue, and muscle insulin sensitivity (P < 0.05), whereas fenofibrate had no effect on insulin action. CONCLUSIONS: Fenofibrate and Niaspan decrease plasma VLDL-TG concentration without altering IHTG content. However, the mechanism responsible for the change in VLDL-TG concentration is different for each drug; fenofibrate increases plasma VLDL-TG clearance, whereas nicotinic acid decreases VLDL-TG secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although the findings regarding the latter effect of PPARα agonism are less consistent than those regarding increases in the activity of lipoprotein lipase. 17-19”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [19]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Notably, also increased adiponectin levels have been reported with metformin treatment, whereas leptin levels remained unchanged [170].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [170]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Self-citationGuerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605
Korenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.075 · Cited by 592
Self-citationTargher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., Zenari, L., & Falezza, G. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3541 · Cited by 574
Gulick, T., Cresci, S., Caira, T., Moore, D. D., & Kelly, D. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11012 · Cited by 560
Ruttmann, E., Brant, L. J., Concin, H., Diem, G., Rapp, K., Ulmer, H., & the Vorarlberg Health Monitoring and Promotion Program Study Group (2005) · Circulation · doi:10.1161/circulationaha.105.552547 · Cited by 556
Non-alcoholic fatty liver disease and increased risk of cardiovascular disease
Targher, G., & Arcaro, G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.021 · Cited by 551
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Lewis, G. F., Uffelman, K. D., Szeto, L. W., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 502
Peroxisome proliferator activated receptor-alpha expression in human liver.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440
Self-citationCarlson, L. A., & Orö, L. (1962) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1962.tb07203.x · Cited by 433
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Westerbacka, J., Corn�r, A., Tiikkainen, M., Tamminen, M., Vehkavaara, S., H�kkinen, A.-M., Fredriksson, J., & Yki-J�rvinen, H. (2004) · Diabetologia · doi:10.1007/s00125-004-1460-1 · Cited by 338
The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects
Chen, X., Iqbal, N., & Boden, G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5479 · Cited by 291
Nicotinic Acid as Therapy for Dyslipidemia in Non—Insulin-Dependent Diabetes Mellitus
Garg, A. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450060069031 · Cited by 286
Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
Grundy, S. M., Mok, H. Y., Zech, L., & Berman, M. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34737-4 · Cited by 270
Athyros, V. G., Mikhailidis, D. P., Didangelos, T. P., Giouleme, O. I., Liberopoulos, E. N., Karagiannis, A., Kakafika, A. I., Tziomalos, K., Burroughs, A. K., & Elisaf, M. S. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104696 · Cited by 248
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
Ganji, S. H., Tavintharan, S., Zhu, D., Xing, Y., Kamanna, V. S., & Kashyap, M. L. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300403-jlr200 · Cited by 227
Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Holden, P., & Tugwood, J. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0220001 · Cited by 201
Kim, H., Haluzik, M., Asghar, Z., Yau, D., Joseph, J. W., Fernandez, A. M., Reitman, M. L., Yakar, S., Stannard, B., Heron-Milhavet, L., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1770 · Cited by 190
Kahn, S. E., Beard, J. C., Schwartz, M. W., Ward, W. K., Ding, H. L., Bergman, R. N., Taborsky, G. J., & Porte, D. (1989) · Diabetes · doi:10.2337/diab.38.5.562 · Cited by 181
Seppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168
Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man
Kesäniemi, Y. A. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340410049031 · Cited by 167
Harano, Y., Yasui, K., Toyama, T., Nakajima, T., Mitsuyoshi, H., Mimani, M., Hirasawa, T., Itoh, Y., & Okanoue, T. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01265.x · Cited by 148
Morgan, J. M., Capuzzi, D. M., & Guyton, J. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00732-2 · Cited by 138
Jin, F.-Y., Kamanna, V. S., & Kashyap, M. L. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.1051 · Cited by 138
Chapter 5 Fatty acid oxidation and its regulation
Bremer, J., & Osmundsen, H. (1984) · New comprehensive biochemistry · doi:10.1016/s0167-7306(08)60123-4 · Cited by 128
Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment
Patterson, B. W., Zhao, G., Elias, N., Hachey, D. L., & Klein, S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32435-4 · Cited by 125
Self-citationPoynten, A. M., Gan, S. K., Kriketos, A. D., O’Sullivan, A., Kelly, J. J., Ellis, B. A., Chisholm, D. J., & Campbell, L. V. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00030-1 · Cited by 112
Impaired β-Cell Function in Human Aging: Response to Nicotinic Acid-Induced Insulin Resistance
Chang, A. M., Smith, M. J., Galecki, A. T., Bloem, C. J., & Halter, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0913 · Cited by 101
Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity
Mittendorfer, B., Patterson, B. W., & Klein, S. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00379.2002 · Cited by 89
Self-citationShepherd, J., Packard, C. J., Stewart, J. M., Atmeh, R. F., Clark, R. S., Boag, D. E., Carr, K., Lorimer, A. R., Ballantyne, D., & Morgan, H. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111643 · Cited by 85
Wang, W., Basinger, A., Neese, R. A., Shane, B., Myong, S.-A., Christiansen, M., & Hellerstein, M. K. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.3.e540 · Cited by 85
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz, S., Wagner, S., Schmitz, M., Bedynek, A., Keller, U., & Demant, T. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300309-jlr200 · Cited by 83
Vega, G. L., Cater, N. B., Meguro, S., & Grundy, S. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.073 · Cited by 79
Miettinen, T. A., Taskinen, M., Pelkonen, R., & Nikkilä, E. A. (1969) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1969.tb01473.x · Cited by 70
Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects
Kelly, J., Lawson, J. A., Campbell, L., Storlien, L., Jenkins, A. B., Whitworth, J. E., & O'Sullivan, A. (2000) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001099 · Cited by 64
Lambe, K. G., Woodyatt, N. J., Macdonald, N., Chevalier, S., & Roberts, R. A. (1999) · Toxicology Letters · doi:10.1016/s0378-4274(99)00151-4 · Cited by 62
Wang, W., Basinger, A., Neese, R. A., Christiansen, M. P., & Hellerstein, M. K. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.1.e50 · Cited by 61
EFFECTS OF FENOFIBRATE AND XUEZHIKANG ON HIGH‐FAT DIET‐INDUCED NON‐ALCOHOLIC FATTY LIVER DISEASE
Hong, X. Z., Li, L. D., & Wu, L. M. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04547.x · Cited by 54
Kissebah, A. H., Alfarsi, S., ADAMS, P. W., Seed, M., Folkard, J., & Wynn, V. (1976) · Atherosclerosis · doi:10.1016/0021-9150(76)90076-9 · Cited by 54
Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.
Packard, C. J., Clegg, R. J., Dominiczak, M. H., Lorimer, A. R., & Shepherd, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38775-7 · Cited by 54
The prevalence of side effects with regular and sustained-release nicotinic acid
Gibbons, L. W., González, V., Gordon, N. F., & Grundy, S. M. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80185-5 · Cited by 53
Alvarsson, M., & Grill, V. (1996) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519609088812 · Cited by 39
Cree‐Green, M., Newcomer, B. R., Read, L. K., Sheffield‐Moore, M., Paddon‐Jones, D., Chinkes, D. L., Aarsland, A. A., & Wolfe, R. R. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.08.001 · Cited by 16
Research works printed but not linked: 1
- Bremer J, Osmundsen H 1984 Fatty acid oxidation and its regulation. In: Numa S, ed. Fatty acid metabolism and its regulation. Amsterdam: Elsevier; 113–154 [Google Scholar]
Cited by
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,610
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“Removal of visceral adipose tissue alone (Fabbrini et al., 2010b) or in conjunction with bariatric surgery does not significantly impact keymetabolic parameters (Andersson et al., 2017; Fabbrini et al., 2010b).”
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Integrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Metadata
- Authors
- Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- Harokopio University of Athens (GR)
- Corresponding author
- Klein, Samuel
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-06
- Volume
- 95
- Issue
- 6
- Pages
- 2727-2735
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2902076
- OpenAlex
- W2055564165
- Semantic Scholar
- 8ac4e4b024d117595373df5ce97953802a1202d0
- Cited by
- 192
- References
- 51
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 16 · 2023: 15 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 14 · 2013: 13 · 2012: 14
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p41rr000954-34, UL1TR000448)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK37948, DK56341, R01DK037948, P30DK056341)
- National Center for Research Resources (P41-RR000954, RR-024992, RR 00954, UL1RR024992)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, fenofibrate, nicotinic acid, Niaspan, apolipoprotein B, insulin sensitivity, insulin resistance, hypertriglyceridemia, obesity, cardiovascular risk factors, hepatic insulin action
- MeSH terms
- Adult, Hypolipidemic Agents, Apolipoproteins B, Blood Glucose, Body Composition, Double-Blind Method, Fatty Acids, Nonesterified, Fatty Liver, Female, Humans, Insulin, Insulin Resistance, Kinetics, Lipoproteins, VLDL, Liver, Male, Middle Aged, Niacin, Obesity, Fenofibrate, Risk Factors, Triglycerides, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.